Increased platelet 5-HT2 receptor binding after electroconvulsive therapy in depression

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Depression is a complex mood disorder often requiring multiple treatment modalities.
• Electroconvulsive treatment (ECT) is an effective therapy for severe, treatment-resistant depression.
• Serotonin (5-HT) pathways are implicated in the pathophysiology of depression.

Purpose of the Study:

• To investigate the impact of electroconvulsive treatment (ECT) on specific serotonin markers in patients with treatment-resistant depression.
• To examine changes in platelet 5-HT2 receptor density and 3H-paroxetine binding following ECT.
• To explore potential correlations between receptor changes and clinical improvement.

Main Methods:

• 12 patients with treatment-resistant depression received an average of 6.1 ECT sessions.
• Platelet 14C-serotonin uptake, 3H-paroxetine binding, and 5-HT2 receptor density were measured before and after ECT.
• Depression severity was assessed using MADRS scores.

Main Results:

• A significant uniform increase in platelet 5-HT2 receptor density was observed post-ECT (p = 0.011).
• Mean reduction in MADRS scores was 80.7% (p < 0.002), indicating significant clinical improvement.
• No significant changes were found in 3H-paroxetine binding (Bmax) or serotonin uptake.

Conclusions:

• Repeated ECT leads to an upregulation of serotonin 5-HT2 receptors in platelets of patients with depression.
• The observed increase in platelet 5-HT2 receptors may reflect similar changes in the cerebral cortex, contributing to ECT's therapeutic effects.
• Further research is warranted to elucidate the precise role of 5-HT2 receptor modulation in ECT response.